Tips for Healthy Ovarian Reserve: Impact of Hydroxyurea on Sickle Cell Disease - Health

Impact of Hydroxyurea on Ovarian Reserve in Patients with Sickle Cell Disease

A recent study published in Blood Advances has found that hydroxyurea , a common drug used to treat Sickle cell disease ( SCD ) , does not affect ovarian reserve in female patients . SCD is a prevalent inherited red blood cell disorder in the United States , affecting around 100,000 individuals . The condition can lead to serious health issues , including vaso - occlusive crisis ( VOC ) , which is a significant cause of death among those with SCD.

The study , led by Dr. Tamara Diesch - Furlanetto from the University Children 's Hospital Basel in Switzerland , aimed to determine the impact of hydroxyurea on fertility in female patients with SCD . It was discovered that the drug does not have any negative effects on ovarian reserve , challenging the long - standing belief that hydroxyurea could reduce fertility in these patients.

"Many female patients with SCD avoid hydroxyurea due to concerns about fertility,"

said Dr. Diesch - Furlanetto . However , the study 's findings suggest that hydroxyurea is a safe and effective therapy for managing SCD symptoms without compromising fertility.

The research involved analyzing ovarian tissue samples collected from female patients with SCD before undergoing stem cell transplantation . The study focused on measuring the density of primordial follicles , which are essential for ovarian function . The results showed no significant difference in follicle density between patients who received hydroxyurea and those who did not , indicating that the drug does not impact ovarian reserve.

Future Implications and Considerations

These findings provide valuable insights for female patients with SCD who may benefit from hydroxyurea treatment . The study suggests that fertility preservation measures prior to starting hydroxyurea therapy may not be necessary , offering reassurance to individuals concerned about the drug 's potential impact on fertility.

Dr. Diesch - Furlanetto emphasized the importance of considering ovarian tissue preservation before undergoing hematopoietic stem cell transplantation , although it is not mandatory for patients solely receiving hydroxyurea treatment . The study results could encourage more individuals to explore hydroxyurea as a viable treatment option for SCD symptoms.

Moving forward , Dr. Diesch - Furlanetto and her team plan to conduct prospective studies to further investigate hydroxyurea 's effects on fertility in patients with SCD . They also aim to explore additional research on ovarian tissue transplantation and its implications for individuals with the condition.

Overall , the study 's findings contribute to a better understanding of the relationship between hydroxyurea and ovarian reserve in female patients with sickle cell disease , providing valuable information for healthcare providers and individuals managing this complex condition.